Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene’s (IMU) phase one metastatic advanced solid tumours (MAST) trial evaluating its novel cancer-killing drug, VAXINIA, progresses to its fourth cohort
- Meanwhile, cohort one of IMU’s combination study using Pembrolizumab is cleared and cohort two is ready to begin
- Imugene MD and CEO Leslie Chong notes the company is moving through its cohorts quickly and aims to have the research peer reviewed and recognised in peer-reviewed publications
- The trial commenced in May 2022 and will run for 24 months, with the funding sourced from Imugene’s existing budgets and resources
- IMU shares are up 7.53 per cent, trading at 10 cents at 12:40 pm AEST
Imugene’s (IMU) phase one metastatic advanced solid tumours (MAST) trial evaluating its novel cancer-killing drug, VAXINIA, has progressed to its fourth cohort of patients.
IMU has completed cohort three of intravenous (IV) monotherapy dose escalations, and its fourth cohort is set to receive a higher-dosed IV monotherapy dosage.
Meanwhile, the company reported cohort one of its IV arm combination study using Pembrolizumab has been cleared, allowing cohort two to be opened.
“As we continue to move through the cohorts at pace, we’re aiming to have this high-quality science peer reviewed and recognised within publications or conferences befitting of its results and potential benefit to patients in need,” Imugene MD and CEO Leslie Chong said.
The multi-centre phase one MAST trial initially began with low doses of VAXINIA to patients with metastatic or advanced solid tumours who had at least two prior lines of standard treatment.
The trial commenced in May 2022 and is anticipated to run for 24 months, with the funding sourced from Imugene’s existing budgets and resources.
IMU shares were up 7.53 per cent, trading at 10 cents at 12:40 pm AEST.
